| Literature DB >> 29376852 |
Alan Tucholka1, Oriol Grau-Rivera1,2, Carles Falcon1,3, Lorena Rami2, Raquel Sánchez-Valle2, Albert Lladó2, Juan Domingo Gispert1,3, José Luis Molinuevo1,2.
Abstract
BACKGROUND: Gray matter changes associated with the progression of Alzheimer's disease (AD) have been thoroughly studied. However, alterations in white matter tracts have received less attention, particularly during early or preclinical stages of the disease.Entities:
Keywords: Alzheimer’s disease; biomarkers; connectivity; diffusion MRI; magnetic resonance imaging; mild cognitive impairment; preclinical stage; tractography
Mesh:
Substances:
Year: 2018 PMID: 29376852 PMCID: PMC5798529 DOI: 10.3233/JAD-170553
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472
Demographics and biomarkers, HCB and ADNI separately, and for HCB and ADNI merged together
| HCB | ADNI | HCB+ADNI | ||||||||||
| NC | Pre | MCI | AD | NC | Pre | MCI | AD | NC | Pre | MCI | AD | |
| N | 40 | 12 | 21 | 14 | 28 | 16 | 23 | 29 | 68 | 28 | 44 | 43 |
| Women/Men | 26/14 | 7/5 | 10/11 | 8/6 | 15/13 | 10/6 | 7/16 | 11/18 | 41/27 | 17/11 | 17/27 | 19/24 |
| Mean Age | 62.1 | 72.7* | 70* | 65.9† | 71.8‡ | 75.8* | 72.4 | 74.2‡ | 66.1 | 74.5* | 71.3* | 71.5* |
| SD | 8.5 | 6 | 7.5 | 9 | 5.1 | 4.6 | 8 | 7.8 | 8.7 | 5.5 | 7.9 | 9.1 |
| Mean education (y) | 11.9 | 10.6 | 11 | 8.6* | 17.2‡ | 16.2‡ | 16.1‡ | 15.2* | 14.1 | 13.8 | 13.7 | 13 |
| SD | 4.4 | 4 | 4.3 | 4.2 | 2.6 | 2.1 | 2.8 | 2.8 | 4.6 | 4.2 | 4.4 | 4.5 |
| 9 | 4 | 10 | 8 | 7 | 8 | 21 | 20 | 16 | 12 | 31 | 28 | |
| Non-carrier | 31 | 8 | 10 | 6 | 21 | 8 | 2 | 9 | 52 | 16 | 12 | 15 |
| Mean Aβ | 760.8 | 375.8 | 339.1 | 310.7 | 239 | 148.5 | 135.7 | 130 | ||||
| SD | 160.3 | 80.1 | 71.9 | 83.9 | 25.7 | 24.1 | 20.7 | 23.1 | ||||
| Mean p-tau | 56.6 | 76.6 | 112.2 | 105.7 | 31.2 | 51.7 | 52.9 | 66.6 | ||||
| SD | 27.7 | 47.8 | 43.7 | 43 | 12.2 | 32.9 | 18.7 | 43 | ||||
*Significantly different versus Control group (p < 0.05); †Significantly different versus Preclinical group (p < 0.05); ‡Significantly different versus same group in HCB population (p < 0.05). NC, normal controls; Pre, preclinical; MCI, mild cognitive impairment due to AD; AD, Alzheimer’s disease patients.
Fig.1Differences in connectivity between the control group and the pre-ad group, when both HCB and ADNI dataset are merged together. Blue lines indicate a decrease of connectivity and red lines an increase.
Fig.2Differences in connectivity between the pre-ad group and the MCI group, when both HCB and ADNI dataset are merged together. Blue lines indicate a decrease of connectivity and red lines an increase.
Fig.3Differences in connectivity between the MCI group and the AD group, when both HCB and ADNI dataset are merged together. Blue lines indicate a decrease of connectivity and red lines an increase.
Fig.4Connections that correlate with level of Aβ when both HCM and ADNI dataset are merged together. Blue lines indicate a positive correlation and red lines a negative one.